Plant ID: NPO23547
Plant Latin Name: Strychnos amazonica
Taxonomy Genus: Strychnos
Taxonomy Family: Loganiaceae
NCBI TaxonomyDB:
1618122
Plant-of-the-World-Online:
n.a.
China
CA2; CA14; CA7; CA4; | |
PPARA; | |
ALOX15; CBR1; | |
XDH; | |
FABP5; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.665E-12 | 5.563E-08 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.616E-11 | 1.446E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.075E-10 | 2.602E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.346E-10 | 5.108E-07 | CA14, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.026E-09 | 1.718E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.517E-09 | 2.359E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.305E-08 | 2.390E-05 | CA14, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.254E-08 | 2.390E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 4.950E-08 | 4.686E-05 | ALOX15, CBR1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.322E-07 | 3.996E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.463E-06 | 8.609E-04 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.790E-06 | 9.743E-04 | CYP19A1, CYP1A1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.134E-06 | 1.106E-03 | CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.924E-06 | 1.447E-03 | CYP1A1, CYP1A2 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.305E-06 | 3.359E-03 | CYP1A2, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.363E-05 | 5.817E-03 | CYP1A1, CYP1A2 |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.188E-05 | 8.989E-03 | CA2, CA7 |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 2.444E-05 | 9.853E-03 | CBR1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.991E-09 | 2.887E-08 | CBR1, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.556E-10 | 1.031E-08 | CA2, CA4, CA7, CA14 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 6.236E-08 | 6.028E-07 | CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.590E-07 | 1.153E-06 | CBR1, CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.657E-06 | 1.284E-05 | CYP1A2, CYP1A1, CYP1B1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 8.033E-06 | 2.588E-05 | CBR1, CYP1A2, ALOX15, CYP1A1, CYP2C19, CYP19A1, XDH |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.249E-06 | 1.903E-05 | CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 9.870E-07 | 5.725E-06 | CYP1A2, ALOX15, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.008E-05 | 2.923E-05 | CBR1, ALOX15, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 9.229E-04 | 2.153E-03 | CYP1A2, CYP1A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.039E-03 | 2.153E-03 | CYP1A2, CYP2C19 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.707E-03 | 5.233E-03 | ALOX15, CYP2C19 |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.039E-03 | 2.153E-03 | FABP5, PPARA |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.142E-04 | 3.010E-04 | CA2, CA4 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 4.545E-06 | 1.883E-05 | CYP1A2, XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH; |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
NA: NA | Edema | NA | CA2; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; |